22 Feb

What Analysts Are Recommending for ELAN and ZTS in February

WRITTEN BY Margaret Patrick

Stock price movements

On February 19, Elanco Animal Health (ELAN) closed at $29.16, 1.49% lower than its previous closing price, 4.14% higher than its 52-week low of $28.00, and 22.47% below its 52-week high of $37.61. Its market capitalization was $10.63 billion, and its trailing-12-month and forward PE ratios are 123.76x and 22.79x, respectively.

Since its fourth-quarter earnings release on February 6, Elanco Animal Health stock has dropped by 3.51% from $30.22 on February 5 to $29.16 on February 19. The company missed consensus revenue estimates by $4.74 million but surpassed the consensus EPS estimate by $0.01 in the fourth quarter.

What Analysts Are Recommending for ELAN and ZTS in February

On February 19, Zoetis (ZTS) closed at $94.91, 0.48% higher than its previous closing price, 23.26% higher than its 52-week low of $77.00, and 1.72% below its 52-week high of $96.57. Its market capitalization was $45.36 billion, and its trailing-12-month and forward PE ratios are 33.24x and 24.42x, respectively.

Since its fourth-quarter earnings release on February 14, Zoetis stock has declined by 0.88% from $29.42 on February 13 to $29.16 on February 19. The company surpassed both of its consensus revenue and consensus EPS estimates by $30 million and $0.02, respectively. Zoetis is trading at a lower trailing PE ratio but higher forward PE ratios as compared to Elanco Animal Health.

Analysts’ recommendations and target price

The 12-month consensus recommendations for Elanco Animal Health and Zoetis are a “buy.” Of the 13 analysts covering Elanco Animal Health, two recommend a “strong buy,” four recommend a “buy,” six recommend a “hold,” and one analyst recommends a “sell.” Their 12-month target price is $34.7, 19.00% higher than its last closing price on February 20. The highest target price estimate for the company is $38, and the lowest is $29.

Of the 15 analysts covering Zoetis, five recommend a “strong buy,” six recommend a “buy,” and four recommend a “hold.” Their 12-month target price is $100.09, 5.46% higher than its last closing price on February 20. The highest target price estimate for the company is $113, and the lowest is $86.

Next, we’ll look at the revenue growth trajectory of Elanco Animal Health and Zoetis in greater detail.

Latest articles

The 2019 Dubai Airshow brought good news for Boeing. The company logged new requests for its troubled 737 MAX aircraft after several months of frozen orders.

A US-China trade deal, which appeared to on the table up until last week, might not happen this year. Yesterday, the Dow Jones fell for a third day.

Netflix has been under pressure since it saw a surprise loss in US subscribers in the second quarter. It's up 14% YTD, the lowest among its FAANG peers.

The case for Apple (AAPL) acquiring Sonos has gotten more compelling. Sonos (SONO) has announced it has acquired Snips for $37.5 million.

In October, PayPal (PYPL) led the exit of one-quarter of Libra's original partners, dealing a blow to Facebook’s (FB) cryptocurrency project.

Facebook CEO Mark Zuckerberg joined Donald Trump for dinner at the White House in October, but both sides kept quiet about the meeting, NBC News has revealed.